Diversity in Clinical TrialsImproving Research Outcomes, Targeted Drug Development
Dr. Coleman Obasaju
Senior Medical Director, Lilly Oncology and
Global Leader, Diversity in Clinical Research
Eli Lilly and Company
Hospitals and pharmas desperately need to get more Blacks, Latinos and Asians in their clinical trials. Learn how pharmaceutical leaders are partnering with not-for-profits to elicit specific information that will improve outcomes for these populations for diseases such as diabetes, heart disease and cancer. Get best practices in using resource groups to find and encourage more diversity in clinical trials.
To access the presentation slides, go to DiversityInc Best Practices.
Dr. Coleman Obasaju
Coleman K. Obasaju, M.D., Ph.D., is the Global Leader for Diversity in Clinical research, Global Medical Affairs Leader for Erbitux and Necitumumab and has responsibility for the US Medical Liaisons, in the Oncology Business Unit(OBU) of Eli Lilly. Dr. Obasaju received his Medical degree at the University College Hospital, Ibadan, Nigeria in 1982. He then went on to pursue post-graduate training in clinical pharmacology and medical oncology in England at the Christie Hospital and the University of Manchester, obtaining both a master’s and a doctorate degree.
Dr. Obasaju completed an Internal Medicine residency program at the University of Pennsylvania Health Systems and then went on to a combined fellowship in medical oncology/hematology in the U.S. at Fox Chase Cancer Center and Temple University Cancer Hospital, both in Philadelphia. He obtained a Clinical Investigator Training Program (CITP) Fellowship awarded by the National Cancer Institute (NCI) prior to joining Eli Lilly and Company in 2001.
Additionally, Dr. Obasaju served for four years as a member of the American Association for Cancer Research (AACR) Minority in Cancer Research Council. In that role, he provided more visibility to the scientific contribution of minority scientists and developed strategies to improve the pipeline of future minority investigators.